A Study to Evaluate Conceptual Saturation of Evaluating Respiratory Symptoms (E-RS) in Subjects With Asthma
A Study to Evaluate Conceptual Saturation of Evaluating Respiratory Symptoms (E-RS) in Subjects With Asthma
Asthma and chronic obstructive pulmonary disease (COPD) are chronic inflammatory conditions
 involving the small airways with airflow limitations resulting from genetic and environmental
 interactions. Currently, there are no existing subject diaries with evidence of
 responsiveness to measure the daily symptoms of asthma. Therefore, there is a need to either
 develop a new symptom diary to characterize subject burden of asthma symptoms or modify/adapt
 an existing tool from a related disease area for use in subjects with moderate to severe
 asthma. The E-RS in COPD (E-RS: COPD®) questionnaire was developed as a measure of daily
 respiratory symptoms associated with COPD. The fixed dose combination of fluticasone furoate/
 umeclidinium/ vilanterol (FF/UMEC/VI) administered via the ELLIPTA® dry powder inhaler (DPI)
 has been developed for the treatment of asthma. This cross-sectional, qualitative study is
 designed to understand the symptoms and disease experience of subjects with moderate to
 severe asthma. This study will also evaluate underlying concepts that are most important to
 asthmatic subjects compared to symptoms and concepts included in the E-RS: COPD and two
 supplemental asthma items (wheeze and shortness of breath with physical activity).
 Approximately 32 subjects will be included in the study and interviewed via telephone. Each
 interview including time for consent, qualitative interview, and completion of case report
 forms (CRFs) is expected to last approximately 60 to 90 minutes. Subjects will be expected to
 complete a daily diary for the next 7 days, following the initial telephone interview. E-RS:
 COPD and ELLIPTA are registered trademarks of GlaxoSmithKline group of companies.
Inclusion Criteria:

 -  Aged 18 years or older at the time of consent.

 -  History of airflow obstruction as indicated by a pre-bronchodilator forced expiratory
 volume in one second (FEV1) <80 percent predicted recorded in the previous 12 months.

 -  Documented evidence of a reversibility assessment within the previous 12 months, which
 demonstrated a post-bronchodilator increase in FEV1 of >=12 percent and >= 200
 milliliters (mL).

 -  Diagnosed with moderate or severe asthma as defined by a stable maintenance inhaled
 corticosteroid (ICS) dose for at least 12 weeks prior to screening of; moderate:
 medium ICS dose > 250 and <=500 micrograms per day (mcg/day) fluticasone propionate
 (or equivalent) based on the total daily maintenance treatment dose; Severe: high ICS
 dose > 500 mcg/day fluticasone propionate (or equivalent) based on the total daily
 maintenance treatment dose.

 -  Documented control status defined using the asthma control questionnaire (ACQ-6) items
 (ACQ-6) obtained at the time of screening.

 -  Able to understand, read and speak English or Spanish sufficiently to complete all
 assessments.

 -  Willing and able to take part in a telephone interview session.

 -  Willing and able to provide written informed consent.

 Exclusion Criteria:

 -  Is a current smoker.

 -  Has any medical condition that would preclude participation in this study, including
 the presence of emphysema or chronic bronchitis (COPD other than asthma) or a
 clinically important lung condition other than asthma such as current infection,
 bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis or diagnoses of an
 eosinophilic disorder such as eosinophilic esophagitis or a history of lung cancer.

 -  Participated in an interventional study within the past 30 days.